Skip to main content

Table 2 Odds of Drug Treatment Categories within 6 Months of MI Among Adults with AS and PsA separately and combined

From: Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study

  Ankylosing Spondylitis Psoriatic Arthritis Combined
  Cases/Controls Fully Adjusted ORb
(95% CI)
Cases/Controls Fully Adjusted ORb
(95% CI)
Cases/Controls Fully Adjusted ORb
(95% CI)
NSAID use only 135/536 1.0 (ref) 106/430 0.84 (0.61, 1.17) 241/966 1.0 (ref)
DMARD use only 37/141 1.04 (0.65, 1.68) 112/432 1.0 (ref) 149/573 1.13 (0.87, 1.48)
TNFi use only < 11a/49 0.85 (0.39, 1.85) > 65a/244 1.09 (0.74, 1.60) 76/293 1.19 (0.85, 1.67)
NSAID, DMARD 27/86 1.29 (0.76, 2.20) 62/248 0.97 (0.67, 1.40) 89/334 1.17 (0.86, 1.58)
NSAID, TNFi 11/29 1.77 (0.79, 3.98) 18/91 0.83 (0.47, 1.48) 29/120 1.15 (0.72, 1.83)
DMARD, TNFi < 11a/34 0.91 (0.38, 2.16) > 20a/96 0.77 (0.45, 1.34) 31/130 0.93 (0.59, 1.47)
NSAID, DMARD, TNFi < 11a/19 1.99 (0.78, 5.12) > 15a/55 1.23 (0.67, 2.25) 26/74 1.55 (0.93, 2.57)
  1. OR Odds ratio, NSAID Nonsteroidal anti-inflammatory drug, TNFi Tumor necrosis factor inhibitor, DMARD Symptom modifying anti-rheumatic drug
  2. aCounts under 11 subjects were not reported to prevent inadvertent subject identification. Additional counts masked to protect back-calculation of these small numbers
  3. bAdjusted for age, chronic kidney disease, diabetes, hypertension, ischemic heart disease, liver disease, peptic ulcer disease, psoriasis, rheumatoid arthritis, obesity, statin use, smoking status, rheumatology visits in the year prior to study eligibility, and erythrocyte sedimentation rate (ESR) or c-reactive protein (CRP) ordered in the year prior to study eligibility